Clinical Trial Update: An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

View source ↗

Summary

An observational study evaluating the effectiveness and tolerability of Rebif 44 µg or 22 µg in chronic multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif 22 µg (interferon beta-1a)
• Rebif 44 µg (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis | Status: COMPLETED